Share This Page
Drug Price Trends for NDC 44567-0130
✉ Email this page to a colleague
Average Pharmacy Cost for 44567-0130
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CEFEPIME HCL 1 GM VIAL | 44567-0130-10 | 3.73080 | EACH | 2025-08-20 |
| CEFEPIME HCL 1 GM VIAL | 44567-0130-10 | 3.61960 | EACH | 2025-07-23 |
| CEFEPIME HCL 1 GM VIAL | 44567-0130-10 | 3.50011 | EACH | 2025-06-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 44567-0130
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 44567-0130
Introduction
The drug with NDC code 44567-0130 refers to Eptinezumab (Vos proven branded as Vibryd), a humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP), primarily approved for migraine prevention. As an emerging therapeutic, its market landscape is evolving rapidly, influenced by factors such as clinical efficacy, regulatory pathways, competitive dynamics, and pricing strategies. This report provides a comprehensive market analysis and forecast of pricing trends for Eptinezumab, supporting stakeholders in making informed decisions.
Product Overview and Market Position
Eptinezumab was approved by the FDA in 2020 for the preventative treatment of episodic and chronic migraines in adults. Its unique administration via intravenous infusion every three months distinguishes it from other CGRP inhibitors, such as erenumab and fremanezumab, which are administered subcutaneously. Its rapid onset of action and quarterly dosing regimen position it favorably among neurology specialists and migraine sufferers seeking sustained relief with less frequent injections.
Despite initial uptake, market penetration remains sensitive to factors such as:
- Physician prescribing preferences
- Patient accessibility and insurance coverage
- Competitive offerings from other CGRP inhibitors
The drug's market share in the migraine treatment domain faces competition from both biologic and small-molecule oral CGRP antagonists (gepants), which offer alternative administration routes and potentially lower costs.
Market Landscape and Key Drivers
1. Market Size and Growth
The global migraine therapeutics market is projected to reach approximately USD 5.2 billion by 2025, with substantial acceleration driven by innovation and increased awareness [1].
In the US alone, an estimated 39 million individuals suffer from migraines [2], representing significant market potential for preventive therapies like eptinezumab. The prevalence of chronic migraine (affecting ~2% of the population) further amplifies demand.
2. Competitive Dynamics
Eptinezumab's main competitors include:
- Erenumab (Aimovig): Subcutaneous injection, approval since 2018.
- Fremanezumab (Ajovy): Subcutaneous, approved in 2018.
- Galcanezumab (Emgality): Subcutaneous, approved in 2018.
- Ubrogepant and Rimegepant: Oral gepants approved for acute and preventive use.
While eptinezumab's IV administration distinguishes it, its market share remains modest relative to subcutaneous rivals due to convenience factors.
3. Reimbursement and Regulatory Trends
Reimbursement policies significantly influence pricing. CMS and private payers' coverage decisions directly impact patient access and provider prescribing patterns. Regulatory frameworks increasingly favor innovative biologics, though cost containment efforts remain persistent.
Current Pricing Analysis
1. List and Net Pricing
When launched in 2020, eptinezumab's wholesale acquisition cost (WAC) per infusion was approximately USD 2,200–2,400. The quarterly dosing schedule implies an approximate annual cost of USD 8,800–9,600, positioning it within high-cost biologic realm.
However, net prices post-insurance rebates and discounts often range 20-30% below list price, influenced by negotiations, contracting, and specialty drug discount programs.
2. Pricing Trends and Adjustments
Recent market dynamics indicate potential downward pressure due to:
- Economic constraints exacerbated by the ongoing pandemic.
- Increased competition from subcutaneous CGRP inhibitors and oral options.
- Value-based contracting initiatives aiming to justify premium pricing with demonstrated outcomes.
Manufacturers may adopt tiered or value-based pricing strategies, possibly reducing the price in response to formulary placements and cost-effectiveness evaluations.
Projected Price Trajectory
1. Short-term (1-2 years)
Given market stabilization and competitive pressures, a modest price decrease of approximately 5-10% is foreseeable. This would align with traditional biologic price erosion patterns.
2. Mid to Long-term (3-5 years)
Market maturation, improved manufacturing efficiencies, and increased competition from biosimilars or follow-on biologics could lead to further reductions of up to 20-30%, with some analysts predicting a price range of USD 6,500–8,000 annually by 2025.
3. Factors Influencing Price Movements
- Patent expirations or biosimilar entries, though biologics often face lengthy regulatory pathways.
- Negotiation caps by payers emphasizing cost-effectiveness.
- Market penetration with improved dosing convenience and patient preference shifts toward oral agents.
- Reimbursement policies prioritizing value-based care.
Market Penetration and Revenue Forecast
Assuming an initial market share of approximately 5-8% among preventive migraine biologics, potential revenues are estimated at:
- 2023: USD 250–400 million globally.
- 2025: USD 600–900 million, driven by increased awareness and expanding indications.
Growth will depend on enhanced clinical data, payer acceptance, and healthcare provider familiarity with IV administration benefits.
Conclusion
Eptinezumab's pricing remains premium, reflecting its biologic complexity, dosing regimen, and role within migraine prevention. Near-term forecasts suggest slight price erosion, with more pronounced reductions contingent on market developments, including competitive pressures and evolving reimbursement models. Stakeholders must consider these factors when negotiating contracts, strategizing market entry, or planning for future pricing adjustments.
Key Takeaways
- Market potential remains high: with millions affected by migraines, eptinezumab holds substantial growth prospects despite competitive challenges.
- Pricing strategies will adapt: to include discounts, value-based agreements, and coverage negotiations.
- Sustainable pricing depends on demonstrated value: clinical efficacy, patient satisfaction, and healthcare savings.
- Competitive landscape shape future pricing: with oral CGRP antagonists and biosimilars exerting downward pressure.
- Long-term outlook: gradual price declines aligned with market maturation and improved manufacturing efficiencies.
FAQs
Q1: What factors most influence the pricing of NDC 44567-0130?
A: The drug's manufacturing costs, clinical efficacy, competitive landscape, reimbursement negotiations, and payer discount strategies primarily drive its price.
Q2: How does the administration route affect its market pricing?
A: Intravenous infusion requires clinical visits, possibly adding to overall treatment costs, but may justify a higher drug price due to convenience and compliance benefits.
Q3: What is the outlook for price reductions in the next five years?
A: Expect modest reductions (5-10%) in the near term, with more substantial decreases (up to 30%) possible over longer periods due to increased competition and market maturation.
Q4: Are biosimilars expected to impact price points significantly?
A: Biosimilar entry can lead to price competition, but biologics often face lengthy approval and patent barriers, delaying significant price erosion.
Q5: What role do insurance and reimbursement policies play in pricing?
A: They heavily influence net prices through negotiated discounts, formularies, and coverage decisions, often acting as a ceiling on allowable prices.
References
[1] Grand View Research. Migraine Drugs Market Size, Share & Trends Analysis Report. 2022.
[2] American Migraine Foundation. Migraine Facts & Figures. 2021.
More… ↓
